التفاصيل البيبلوغرافية
| العنوان: |
TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. |
| المؤلفون: |
CRETNEY, ERIKA, SHANKER, ANIL, YAGITA, HIDEO, SMYTH, MARK J., SAYERS, THOMAS J. |
| المصدر: |
Immunology & Cell Biology; Feb2006, Vol. 84 Issue 1, p87-98, 12p |
| مصطلحات موضوعية: |
LIGANDS (Biochemistry), AUTOIMMUNITY, TUMOR necrosis factors, THERAPEUTICS, APOPTOSIS, CANCER patients, CLINICAL trials |
| مستخلص: |
Recombinant, soluble TNF-related apoptosis-inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL-mediated apoptosis and discuss the potential molecular basis for their sensitization. [ABSTRACT FROM AUTHOR] |
|
Copyright of Immunology & Cell Biology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
